See live MACI case videos
Important Safety Information
Full Prescribing Information
Cartilage Repair Blog
Go to Patient Site
Go to Patient Site

Intended for U.S. health care professionals only

Technique Videos

Arthroscopic Delivery Now Approved
Arthroscopic Delivery Now Approved

MACI Arthro instrumentation is designed to create a reproducible technique for arthroscopic delivery while maintaining cell viability on the implant.1

Michael A. Kuhn, MD performs the MACI Arthro procedure on cadaver with a medial femoral condyle defect of the right knee.

The information contained in the following videos does not constitute medical advice. The information regarding surgical techniques are general guidelines and you should use your experiences and the patient’s circumstances when considering the use of the techniques. Individual results will vary among patients and depend on many factors.

  • Trochlea
  • Concomitant

Michael Banffy, MD performs MACI open with a tibial tubercle osteotomy and medial patellofemoral ligament reconstruction on a cadaver with a trochlea cartilage defect.

  • Trochlea

Brian Cole, MD performs the MACI open procedure on a 20-year-old male athlete with cartilage delamination of the central-lateral trochlea.

  • Trochlea

Grant H. Garcia, MD performs a MACI open procedure on a 23-year-old male with a trochlear defect.

  • Condyle
  • Concomitant

Deryk Jones, MD performs the MACI open procedure with a meniscal allograft transfer on a cadaver.

  • Condyle
  • Trochlea

Kai Mithoefer, MD performs a MACI open procedure on a 42-year-old male with multiple cartilage defects to the lateral femoral condyle and trochlea.

  • Trochlea
  • Concomitant

Eric Strauss, MD performs the MACI open procedure with a tibial tubercle osteotomy on a 41-year-old active male with a full-thickness chondral lesion of the central trochlea.

  • Patella
  • Concomitant

Seth L. Sherman, MD demonstrates a MACI open procedure with a tibial tubercle osteotomy using the MD3T™ System on a cadaver with a patella cartilage defect.

  • Condyle
  • Trochlea

Kai Mithoefer, MD performs a MACI open procedure on a 44-year-old female with multiple cartilage defects to the medial femoral condyle and trochlea.

  • Condyle

Robert Burke, MD performs the MACI open procedure on a 37-year-old female with a history of chronic knee pain and a lateral femoral condyle cartilage defect.

  • Patella
  • Trochlea
  • Concomitant

Paul E. Caldwell, MD performs a MACI open procedure with a tibial tubercle osteotomy on a 24-year-old 4th year medical student with patella and trochlea cartilage defects.

  • Condyle
  • Patella
  • Concomitant

Justin Newman, MD performs a MACI open procedure with concomitant TTO, MPFL, and trochleoplasty on a nearly 20-year-old female with LFC and patella cartilage defects.

  • Condyle
  • Concomitant

Joseph Czarnecki, MD performs the MACI open procedure with an ACL reconstruction on a 42-year-old female with a left femoral condyle cartilage defect.

  • Condyle
  • Concomitant

Cassandra Lee, MD performs a MACI open procedure with a subtotal medial meniscectomy on a 29-year-old active female with a medial femoral condyle cartilage defect.

  • Patella
  • Concomitant

Clayton Nuelle, MD performs a MACI open procedure with a tibial tubercle osteotomy on a 22-year-old female with years of bilateral anterior knee pain and swelling with a patella cartilage defect.

  • Condyle
  • Concomitant

Molly Tatum, MD performs the MACI open procedure, meniscus repair, and ACL revision on a 30-year-old female with a medial femoral condyle cartilage defect.

  • Patella
  • Concomitant

Jocelyn Wittstein, MD performs the MACI open procedure and anteromedialization with a tibial tubercle osteotomy on a 35-year-old active female with a patella cartilage defect.

VuMedi Logo

MACI videos, including case studies and best practices are available at VuMedi.

Visit VuMedi now 

#
Question Icon

Questions about the MACI procedure? Have materials sent to your practice.

Request more info 

Reference: 1. Data On File (design history files 21-087-TR and 21-081-TR).

Indication and Important Safety Information

Important Safety Information

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.

Warnings and Precautions:
  • Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be possible.
  • Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
  • Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI implantation.
  • Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:
  • Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
  • The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

MACI® is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.

Safety and effectiveness of MACI in patients over the age of 55 years have not been established.